NDAINJECTIONINJECTABLE
Approved
Jun 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THEELIN (estrone) is an injectable estrogen hormone approved in 1941 for treating female infertility. It works by providing exogenous estrogen to support ovulation and reproductive function in women unable to conceive naturally.
LOE Approaching
Product approaching loss of exclusivity with minimal recent spending data; team focus likely on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THEELIN presents minimal career growth potential; positions are defensive in nature focused on lifecycle management, regulatory maintenance, and eventual product discontinuation or divestiture. Career development on this asset is limited by its mature stage and lack of clinical innovation.
Product Manager (Legacy/Lifecycle)Regulatory Affairs Specialist
Worked on THEELIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.